Alkermes plc diskutieren
Alkermes plc
WKN: A1JKVH / Symbol: ALKS / Name: Alkermes / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
?
-0,13 %
Alkermes (NASDAQ:ALKS) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating and a $50.00 price target on the stock.
Ratings data for ALKS provided by MarketBeat
Alkermes (NASDAQ:ALKS) had its price target lowered by analysts at Deutsche Bank Aktiengesellschaft from $55.00 to $45.00. They now have a "buy" rating on the stock.
Ratings data for ALKS provided by MarketBeat
Alkermes (NASDAQ:ALKS) had its price target lowered by analysts at Wells Fargo & Company from $42.00 to $37.00. They now have an "overweight" rating on the stock.
Ratings data for ALKS provided by MarketBeat
Alkermes (NASDAQ:ALKS) had its price target raised by analysts at Truist Financial Corporation from $50.00 to $55.00. They now have a "buy" rating on the stock.
Ratings data for ALKS provided by MarketBeat
Alkermes (ALKS) had its price target raised by Wells Fargo & Company from $37.00 to $43.00. They now have an "overweight" rating on the stock.
Ratings data for ALKS provided by MarketBeat
Alkermes (ALKS) had its price target lowered by Royal Bank Of Canada from $47.00 to $45.00. They now have an "outperform" rating on the stock.
Ratings data for ALKS provided by MarketBeat
Alkermes (ALKS) had its price target lowered by Piper Sandler from $45.00 to $43.00. They now have an "overweight" rating on the stock.
Ratings data for ALKS provided by MarketBeat
Alkermes (ALKS) had its "buy" rating reaffirmed by UBS Group AG.
Ratings data for ALKS provided by MarketBeat
Alkermes (ALKS) had its price target raised by Wells Fargo & Company from $43.00 to $44.00. They now have an "overweight" rating on the stock.
Ratings data for ALKS provided by MarketBeat
Neueste Beiträge
Stephens in Cognex Corp. diskutieren